Genetic Polymorphisms of the Human MDR1 Drug Transporter

Annual Review of Pharmacology and Toxicology

Volumn 43, Issue , 2003, Pages 285-307

  Schwab, Matthias ^a   Eichelbaum, Michel ^a,b   Fromm, Martin F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

ABC transporter; Drug disposition; P glycoprotein; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; AMPRENAVIR; ATORVASTATIN; BUNITROLOL; CARRIER PROTEIN; CELIPROLOL; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIGITOXIN; DILTIAZEM; DOCETAXEL; DOMPERIDONE; DOXORUBICIN; ENVIRONMENTAL CHEMICAL; ERYTHROMYCIN; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1 TRANSPORTER; NORTRIPTYLINE; PROTEINASE INHIBITOR; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; XENOBIOTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; BILIARY EXCRETION; BRAIN PROTECTION; DISEASE PREDISPOSITION; DRUG DISPOSITION; DRUG EFFECT; DRUG INTERACTION; DRUG RESPONSE; ENTERITIS; EPITHELIUM TUMOR; ETHNIC DIFFERENCE; ETHNIC GROUP; FETUS; GASTROINTESTINAL ABSORPTION; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUMOR; MDR1 GENE; NUCLEOTIDE SEQUENCE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS; TOXICOKINETICS; URINARY EXCRETION; GENETICS; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS;

GENES, MDR; HUMANS; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0038207541     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.43.100901.140233     Document Type: Review

References (109)

1. Tirona RG, Kim RB. 2002. Pharmacogenomics of drug transporters. In Pharmacogenomics. The Search for Individualized Therapies, ed. J Licinio, M-L Wong, pp. 179-213. Weinheim, Germany: Wiley-VCH
2. Dean M, Hamon Y, Chimini G. 2001. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42:1007-17
3. Klein I, Sarkadi B, Varadi A. 1999. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1461:237-62
4. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-62
5. Gottesman MM, Ambudkar SV, Cornwell MM, Pastan I, Germann UA. 1996. Multidrug resistance transporter. In Molecular Biology of Membrane Transport Disorders, ed. SG Schultz, pp. 243-57. New York: Plenum
6. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-98
7. Higgins CF, Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:18-21
8. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-34
9. Watkins PB. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:161-70
10. Suzuki H, Sugiyama Y. 2000. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12:3-12
11. Benet LZ, Cummins CL. 2001. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev. 50(Suppl. 1):S3-11
12. Ayrton A, Morgan P. 2001. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-97
13. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, et al. 1999. Interrelationship between substrates and inhibitors of human CYP3A and P-glykoprotein. Pharm. Res. 16:408-14
14. Doering W. 1979. Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N. Engl. J. Med. 301:400-4
15. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-705
16. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. 1999. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-57
17. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, et al. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-53
18. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, et al. 2000. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:345-55
19. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, et al. 2000. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604
20. Müller M. 2000. Transcriptional control of hepatocanalicular transporter gene expression. Semin. Liver Dis. 20:323-37
21. Geick A, Eichelbaum M, Burk O. 2001. Nuclear response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:14581-87
22. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, et al. 1998. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91:1749-56
23. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, et al. 1989. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem. Biophys. Res. Commun. 162:224-31
24. Fairchild CR, Moscow JA, O'Brien EE, Cowan KH. 1990. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol. Pharmacol. 37:801-9
25. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, et al. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-78
26. Declèves X, Chevillard S, Charpentier C, Vielh P, Laplanche JL. 2000. A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Hum. Mutat. 15:486
27. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, et al. 2001. Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians. Clin. Pharmacol. Ther. 69:169-74
28. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, et al. 2001. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-84
29. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, et al. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-99
30. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, et al. 2001. Application of DHPLC to detect known and novel mutations in the MDR1 gene in different ethnicities. Pharmacol. Toxicol. 89(Suppl. I):105 (Abstr.)
31. + natural killer cells. Pharmacogenetics 11:1-6
32. Nauck M, Stein U, von KS, Marz W, Wieland H. 2000. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin. Chem. 46:1995-97
33. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, et al. 2001. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297:1137-43
34. Furuno T, Landi M-T, Ceroni M, Caporaso N, Bemucci I, et al. 2002. Expression polymorphisms of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. In press
35. Tang K, Ngoi S-M, Gwee P-C, Chua JMZ, Lee EJD, et al. 2002. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 12:437-50
36. Chambers TC, Pohl J, Raynor RL, Kuo JF. 1993. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J. Biol. Chem. 268:4592-95
37. Shen LX, Basilion JP, Stanton VPJ. 1999. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc. Natl. Acad. Sci. USA 96:7871-76
38. Maquat LE. 2001. The power of point mutations. Nat. Genet. 27:5-6
39. Allain FH, Gubser CC, Howe PW, Nagai K, Neuhaus D, et al. 1996. Specificity of ribonucleoprotein interaction determined by RNA folding during complex formulation. Nature 380:646-50
40. Shen LX, Tinoco IJ. 1995. The structure of an RNA pseudoknot that causes efficient frameshifting in mouse mammary tumor virus. J. Mol. Biol. 247:963-78
41. Addess KJ, Basilion JP, Klausner RD, Rouault TA, Pardi A. 1997. Structure and dynamics of the iron responsive element RNA: implications for binding of the RNA by iron regulatory binding proteins. J. Mol. Biol. 274:72-83
42. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM 2002. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62:1-6
43. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, et al. 1995. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376:246-49
44. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, et al. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-60
45. Lindholm A, Welsh M, Alton C, Kahan BD. 1992. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. Pharmacol. Ther. 52:359-71
46. Andrews PA, Sen M, Chang RW. 1996. Racial variation in dosage requirements of tacrolimus. Lancet 348:1446
47. Min DI, Lee M, Ku YM, Flanigan M. 2000. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin. Pharmacol. Ther. 68:478-86
48. Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, et al. 2001. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69:24-31
49. Siegsmund M, Brinkmann U, Schaeffeler E, Weirich G, Schwab M, et al. 2002. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13:1847-54
50. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, et al. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenentics study. Lancet 359:30-36
51. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, et al. 2002. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71:297-303
52. Yoon Y, Chun H, Kim E, Shon J, Bae K, et al. 2002. Genetic and environmental factors influencing on the disposition of digoxin: a population pharmacokinetic approach. Clin. Pharmacol. Ther. 71:P73 (Abstr.)
53. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, et al. 2001. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:1400-4
54. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-24
55. Kerb R, Aynacioglu AS, Brockmöller J, Schlagenhaufer R, Bauer S, et al. 2001. The predictive value of MDR1, CYP2C9, and CYP2C 19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1:204-10
56. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, et al. 2002. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53:526-34
57. Shon J, Chun H, Kim K, Kim E, Yoon Y, et al. 2002. The PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects. Clin. Pharmacol. Ther. 71:P71 (Abstr.)
58. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, et al. 2001. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47:1048-52
59. Giessmann T, Ludwig K, Franke G, Popowski K, Zschiesche M, et al. 2001. The disposition of talinolol is influenced by the MDR1 genotype in man. Naunyn-Schmiedeberg's Arch. Pharmacol. 363(Suppl.):R120 (Abstr.)
60. Pauli-Magnus C, Feiner J, Brett C, Lin ET, Kroetz DL. 2002. No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide. Clin. Pharmacol. Ther. 71:P72 (Abstr.)
61. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27:866-71
62. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, et al. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-94
63. Alsenz J, Steffen H, Alex R. 1998. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Coco-2 cell monolayers. Pharm. Res. 15:423-28
64. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, et al. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-601
65. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, et al. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:1206-12
66. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, et al. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:655-60
67. Huisman MT, Smit JW, Schinkel AH. 2000. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14:237-42
68. Stanulla M, Schaeffeler E, Schrappe M, Rathmann A, Arens S, et al. 2001. An association between the MDR1 C3435T polymorphism and CNS relapse in childhood acute lymphoblastic leukemia. Blood 98:317a (Abstr.)
69. Uhr M, Steckler T, Yassouridis A, Holsboer F. 2000. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-87
70. Roberts R, Joyce P, Mulder RT, Begg EJ, Kennedy MA. 2002. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypertension in patients treated for major depression. Pharmacogenomics J. 2:191-96
71. Schinkel AH. 1997. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 8:161-70
72. Farrell RJ, Peppercorn MA. 2002. Ulcerative colitis. Lancet 359:331-40
73. Shanahan F. 2002. Crohn's disease. Lancet 359:62-69
74. Taylor KD, Yang H, Rotter JI. 2001. Inflammatory bowel disease. II. Gene mapping. Mol. Genet. Metab. 74:22-44
75. Panwala CM, Jones JC, Viney JL. 1998. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161:5733-44
76. Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, et al. 2002. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am. J. Pathol. 160:739-51
77. Schwab M, Schaeffeler E, Marx C, Fromm MF, Metzler J, et al. 2002. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gut. In press (Abstr.)
78. Maimone D, Dominici R, Grimaldi LM. 2001. Pharmacogenomics of neurodegenerative diseases. Eur. J. Pharmacol. 413:11-29
79. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-98
80. Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, Roden DM. 1997. Dietary salt increases first-pass elimination of oral quinidine. Clin. Pharmacol. Ther. 61:292-300
81. Darbar D, Fromm MF, Dell'Orto S, Kim RB, Kroemer HK, et al. 1998. Modulation by dietary salt of verapamil disposition in humans. Circulation 98:2702-8
82. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, et al. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-72
83. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. 2001. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29:1454-59
84. Jette L, Murphy GF, Leclerc JM, Beliveau R. 1995. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Pharmacol. 50:1701-9
85. Wu X, Whitfield LR, Stewart BH. 2000. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid cotransporter. Pharm. Res. 17:209-15
86. Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, et al. 1999. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm. Drug Dispos. 20:85-90
87. Karlsson J, Kuo SM, Ziemniak J, Artursson P. 1993. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009-16
88. Desrayaud S, Guntz P, Scherrmann JM, Lemaire M. 1997. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. 61:153-63
89. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. 1993. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:6077-80
90. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, et al. 2000. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat. Rev. 26:449-62
91. Pauli-Magnus C, Mürdter T, Godel A, Mettang T, Eichelbaum M, et al. 2001. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedeberg's Arch. Pharmacol. 363:337-43
92. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. 1993. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324:99-102
93. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, et al. 1994. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48:1528-30
94. Schuetz EG, Yasuda K, Arimori K, Schuetz JD. 1998. Human MDR1 and mouse mdr1 a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. Arch. Bioch. Biophys. 350:340-47
95. Sugiyama Y, Kato Y, Chu X. 1998. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 42(Suppl.):S44-49
96. Ito T, Yano I, Tanaka K, Inui KI. 1997. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J. Pharmacol. Exp. Ther. 282:955-60
97. Soldner A, Benet LZ, Mutschler E, Christians U. 2000. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br. J. Pharmacol. 129:1235-43
98. Relling MV. 1996. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther. Drug Monit. 18:350-56
99. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, et al. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-35
100. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. 1996. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 93:4001-5
101. de Lange E, Marchand S, van den Berg D, van der Sandt I, de Boer A, et al. 2000. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12:85-93
102. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, et al. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:24248-52
103. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, et al. 1996. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514-22
104. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, et al. 2000. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther. 293:376-82
105. Hoki Y, Fujimori A, Pommier Y. 1997. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. 40:433-38
106. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
107. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, et al. 1990. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 265:506-14
108. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, et al. 2001. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383-84
109. Ameyaw M-M, Regateiro F, Li T, Liu X, Tariq M, et al. 2001. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217-21